Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Abeona Therapeutics, a developer of gene therapies for lysosomal storage diseases, is paying Regenxbio at least $40 million for access to its adeno-associated virus 9 (AAV9) technology, used to deliver gene therapies into cells. Regenxbio could earn up to $140 million more. Abeona will use the technology in experimental therapies for Sanfilippo syndrome and Batten disease. Another user of Regenxbio’s AAV9 is Novartis, which expects the U.S. Food & Drug Administration to approve its spinal muscular atrophy therapy packaged in AAV9 next year.
This article has been sent to the following recipient: